Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 78c, Beats on Revenue; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 8, 2023 4:11 PM EST   Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY
Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License
Third Quarter 2023 Non-GAAP Net Income of $55.9 Million, $0.49 per Share Diluted
Reported U.S. FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy
sNDA Seeking to Increase FIRDAPSE® Maximum Daily Dose to 100 mg Accepted for Filing by the FDA
Two New... More
